NASDAQ: MURAMural Oncology PLC Stock
$2.70+0.28 (+11.57%)
Updated Apr 17, 2025
MURA Price
$2.70
Fair Value Price
$6.34
Market Cap
$46.52M
52 Week Low
$0.95
52 Week High
$4.74
P/E
-0.36x
P/B
0.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$128.51M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$129M
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MURA Overview
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MURA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MURA
Ranked#338 of 463
Ranked#338 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important MURA news, forecast changes, insider trades & much more!
MURA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MURA ($2.70) is undervalued by 57.39% relative to our estimate of its Fair Value price of $6.34 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MURA ($2.70) is significantly undervalued by 57.39% relative to our estimate of its Fair Value price of $6.34 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MURA due diligence checks available for Premium users.
Valuation
MURA fair value
Fair Value of MURA stock based on Discounted Cash Flow (DCF)
Price
$2.70
Fair Value
$6.34
Undervalued by
57.39%
MURA ($2.70) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MURA ($2.70) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
-177.72x
Market
27.98x
MURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.33x
Industry
4.05x
MURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$34.3M
Profit Margin
0%
MURA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$169.4M
Liabilities
$28.9M
Debt to equity
0.21
MURA's short-term assets ($152.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MURA's short-term assets ($152.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.8M
Investing
$36.2M
Financing
$0.0
MURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MURA vs Biotech Stocks
Mural Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.